How many drugs treat Narcolepsy?

Drug Landscape tracks 9 marketed treatments for Narcolepsy (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/narcolepsy.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Narcolepsy — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Narcolepsy (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Narcolepsy, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Wakix	PITOLISANT	Harmony		Histamine H3 receptor	2019-01-01
Nuvigil	ARMODAFINIL	Nuvo Pharms	armodafinil	D(2) dopamine receptor	2007-01-01
Provigil	modafinil	Nuvo Pharms	Sympathomimetic-like Agent [EPC]	D(2) dopamine receptor	1998-01-01
Amphetamine Sulfate	AMPHETAMINE SULFATE	Azurity	Central Nervous System Stimulant	Sodium-dependent dopamine transporter	1955-01-01
Amphetamine Sulfate	amfetamine	UCB	Central Nervous System Stimulant	Sodium-dependent dopamine transporter	1955-01-01
Xelstrym	dexamfetamine	UCB	Central Nervous System Stimulant [EPC]	Sodium-dependent noradrenaline transporter	1955-01-01
Ritalin	methylphenidate	Novartis		Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptor, Alpha-2C adrenergic receptor
Concerta	Concerta	Lei Lei, MD		Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptor, Alpha-2C adrenergic receptor
Xyrem	Xyrem	Jazz Pharmaceuticals		Calcium/calmodulin-dependent protein kinase type II subunit alpha, GABA-B receptor, Gamma-hydroxybutyrate receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Narcolepsy:

Cite this brief

Drug Landscape (2026). Narcolepsy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/narcolepsy. Accessed 2026-06-10.

Narcolepsy full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing